According to a May 6 news release from drug developer Lykos Therapeutics, the committee will convene June 4 to consider Lykos’ application for MDMA capsules used in combination with psychological intervention.
The meeting will be the first time an FDA advisory committee has reviewed a new PTSD treatment in 25 years.
Final trials conducted by Lykos showed MDMA, also known as ecstasy, was effective in reducing PTSD symptoms when used alongside talk therapy, according to a New York Times report.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
